FDA approved Emergency IND Use of Humanigen’s lenzilumab for compassionate use in COVID-19 patients
On Apr. 2, 2020, Humanigen announced that the company had submitted an initial protocol synopsis to the U.S. Food and Drug Administration (FDA) in support of the company’s plans to initiate a multi-center, U.S., Phase III study in COVID-19 patients
Tags:
Source: Humanigen
Credit:
